Anavex Life Sciences Corp (AVXL)

[frrol]

Group 4 includes Groups 1, 2, and 3. So what it may show, in our extremely small Phase 2A sample, is that wtSIGMAR1 is the biggest efficacy factor, and that it potentiates all other factors like APOE allele, disease stage, and drug concentration. That's good because wtSIGMAR1 is by far the most common.

If this proves out in the advanced Phase 2's, we could use it for qualification criteria in Phase 3's, or just continue to use it for results stratification. Regulators would say what they want to see.